Should I buy or sell Monte Rosa Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GLUE shares. View GLUE analyst ratings or view top-rated stocks .

What is Monte Rosa Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 12 month target prices for Monte Rosa Therapeutics' shares. Their GLUE share price targets range from $11.00 to $18.00. On average, they predict the company's share price to reach $13.33 in the next year. This suggests a possible upside of 327.4% from the stock's current price. View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts .

How have GLUE shares performed in 2023?

Monte Rosa Therapeutics' stock was trading at $7.61 on January 1st, 2023. Since then, GLUE shares have decreased by 59.0% and is now trading at $3.12. View the best growth stocks for 2023 here .

When is Monte Rosa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our GLUE earnings forecast .

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) posted its earnings results on Thursday, November, 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.05.

What ETF holds Monte Rosa Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 18,664 shares of GLUE stock, representing 1.26% of its portfolio.

When did Monte Rosa Therapeutics IPO?

(GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.

Who are Monte Rosa Therapeutics' major shareholders?

Monte Rosa Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (11.99%), Northern Trust Corp (0.89%), Charles Schwab Investment Management Inc. (0.49%), TD Asset Management Inc (0.39%), California State Teachers Retirement System (0.09%) and Legal & General Group Plc (0.07%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Monte Rosa Therapeutics Stock Price, News & Analysis (NASDAQ:GLUE)

$3.12

+0.02 (+0.65%)

(As of 12/1/2023 ET)

Compare

Today's Range: $2.92
▼
$3.16
50-Day Range: $2.50
▼
$6.39
52-Week Range: $2.44
▼
$9.83

Volume: 346,068 shs
Average Volume: 182,680 shs
Market Capitalization: $156.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.33

Monte Rosa Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 327.4% Upside
$13.33 Price Target
Short Interest: Bearish
9.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.56) to ($2.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

446th out of 952 stocks

Biological Products, Except Diagnostic Industry

74th out of 161 stocks

3.3

Analyst's Opinion

Consensus Rating
Monte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.33, Monte Rosa Therapeutics has a forecasted upside of 327.4% from its current price of $3.12.
Amount of Analyst Coverage
Monte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.69% of the float of Monte Rosa Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Monte Rosa Therapeutics has recently decreased by 8.66%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Monte Rosa Therapeutics does not currently pay a dividend.
Dividend Growth
Monte Rosa Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLUE.

3.3

News and Social Media Coverage

News Sentiment
Monte Rosa Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for GLUE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
2 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Monte Rosa Therapeutics is held by insiders.
Percentage Held by Institutions
80.05% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($2.56) to ($2.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Monte Rosa Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Monte Rosa Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Monte Rosa Therapeutics has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

GLUE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GLUE Stock News Headlines

November 21, 2023 | finance.yahoo.com

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

November 14, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)

November 9, 2023 | benzinga.com

Monte Rosa Therapeutics: Q3 Earnings Insights

November 9, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 9, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Inc (GLUE) Reports Q3 2023 Financial Results and Strategic Developments

November 7, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

October 31, 2023 | nasdaq.com

Monte Rosa Therapeutics, Inc. Common Stock (GLUE)

October 31, 2023 | msn.com

Monte Rosa Therapeutics: Roche Partnership Deal Could Bring Added Value

October 30, 2023 | marketwatch.com

Monte Rosa Therapeutics Shares Rise for Second Session in a Row

October 26, 2023 | msn.com

Monte Rosa Therapeutics prices offering to raise $25M

October 26, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

October 24, 2023 | finance.yahoo.com

Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)

October 20, 2023 | msn.com

JP Morgan Maintains Monte Rosa Therapeutics (GLUE) Overweight Recommendation

October 17, 2023 | bizjournals.com

Roche signs $2.5B deal with Boston's Monte Rosa Therapeutics

October 17, 2023 | msn.com

Roche in pact with Monte Rosa to develop cancer and neuro drugs

October 17, 2023 | markets.businessinsider.com

Monte Rosa Therapeutics Inks Strategic Collaboration With Roche To Develop Molecular Glue Degraders

October 17, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

October 17, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

September 16, 2023 | finance.yahoo.com

GLUE - Monte Rosa Therapeutics, Inc.

August 10, 2023 | finanznachrichten.de

Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 10, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

July 27, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

July 16, 2023 | finance.yahoo.com

We're Keeping An Eye On Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

May 30, 2023 | finance.yahoo.com

Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

See More Headlines

Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLUE
CUSIP: N/A
CIK: 1826457
Web: www.monterosatx.com
Phone: 617-949-2643
Fax: N/A
Employees: 133
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.33
High Stock Price Target: $18.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +327.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,500,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -58.20%
Return on Assets: -44.96%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.09
Quick Ratio: 8.09

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.68 per share
Price / Book: 0.85

Miscellaneous

Outstanding Shares: 50,080,000
Free Float: 47,427,000
Market Cap: $156.25 million
Optionable: Not Optionable
Beta: 0.99

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Markus Warmuth M.D. (Age 52)
President, CEO & Director
Comp: $901.35k
Dr. Owen B. Wallace Ph.D. (Age 54)
Chief Scientific Officer
Comp: $630.68k
Dr. Filip Janku M.D. (Age 48)
Ph.D., Chief Medical Officer
Comp: $658.66k
Ms. Jennifer Champoux
Chief People & Operations Officer
Dr. Sharon Townson Ph.D. (Age 48)
Chief Technology Officer
Mr. Philip Nickson J.D. (Age 44)
Ph.D., General Counsel
Dr. John C. Castle Ph.D. (Age 52)
Chief Data Scientist
Dr. Jullian G. Jones J.D. (Age 47)
M.B.A., Ph.D., Chief Business Officer
Mr. Magnus Walter DPHIL
Senior Vice President of Chemical Sciences & Process Development
Mr. Edmund Dunn (Age 57)
Vice President & Corporate Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell Monte Rosa Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GLUE shares.
View GLUE analyst ratings or view top-rated stocks.
What is Monte Rosa Therapeutics' stock price target for 2024?: 3 Wall Street analysts have issued 12 month target prices for Monte Rosa Therapeutics' shares. Their GLUE share price targets range from $11.00 to $18.00. On average, they predict the company's share price to reach $13.33 in the next year. This suggests a possible upside of 327.4% from the stock's current price.
View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts.
How have GLUE shares performed in 2023?: Monte Rosa Therapeutics' stock was trading at $7.61 on January 1st, 2023. Since then, GLUE shares have decreased by 59.0% and is now trading at $3.12.
View the best growth stocks for 2023 here.
When is Monte Rosa Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our GLUE earnings forecast.
How were Monte Rosa Therapeutics' earnings last quarter?: Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) posted its earnings results on Thursday, November, 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.05.

What ETF holds Monte Rosa Therapeutics' stock ?: Range Cancer Therapeutics ETF holds 18,664 shares of GLUE stock, representing 1.26% of its portfolio.
When did Monte Rosa Therapeutics IPO?: (GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.
Who are Monte Rosa Therapeutics' major shareholders?: Monte Rosa Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (11.99%), Northern Trust Corp (0.89%), Charles Schwab Investment Management Inc. (0.49%), TD Asset Management Inc (0.39%), California State Teachers Retirement System (0.09%) and Legal & General Group Plc (0.07%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L.
How do I buy shares of Monte Rosa Therapeutics?: Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GLUE) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial